Lars E. Bryld
Roskilde, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: January 14, 2026
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.
Journal: JAMA dermatology
Published: January 07, 2026
Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis - A Nationwide Cohort Study.
Journal: Clinical and experimental dermatology
Published: September 15, 2025
Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study.
Journal: Clinical and experimental dermatology
Published: September 15, 2025
Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.
Journal: Acta dermato-venereologica
Published: November 25, 2024
Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.
Journal: Acta dermato-venereologica
Published: May 09, 2023
Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 29, 2023
Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study.
Journal: Journal of the American Academy of Dermatology
Published: November 28, 2022
Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort Study.
Journal: The Journal of investigative dermatology
Published: October 05, 2022
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Journal: Seminars in arthritis and rheumatism
Published: December 09, 2021
Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 22, 2021
Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
Journal: JAMA dermatology
Published: April 07, 2021
Last Updated: 09/26/2026